Clinical trials
High Grade Serous Ovarian Cancer clinical trials
Below are recruiting high grade serous ovarian cancer clinical trials, each written for real people, not researchers. We’re tracking 155 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06777082Recruiting
Study of RPL8 protein in ovarian cancer
This study looks at a protein called RPL8 in a specific type of ovarian cancer called high-grade serous ovarian carcinoma. It may help researchers understand the disease better and find new ways to treat it.
Bologna, BOAges 18 years+ - NCT04846933Recruiting
Testing extra scans and data to guide ovarian cancer treatment
This trial collects information from people with suspected ovarian cancer and uses it to improve diagnosis and help predict which treatments may work. It may also look for targeted options, based on scan and medical data results.
TurkuAges 18 years+ - NCT07472140RecruitingPhase 2/Phase 3
PARP inhibitor with or without anti-angiogenesis drug for ovarian cancer
This trial tests whether adding a drug that blocks blood vessel growth (angiogenesis inhibitor) to a PARP inhibitor works better than the PARP inhibitor alone for ovarian, fallopian-tube, or peritoneal cancers that have a specific DNA repair problem called HRD. It aims to find a more effective treatment for people with these cancers.
Minsk, LesnoyAges 18–75 - NCT07460180RecruitingPhase 1/Phase 2
PARP inhibitor with chemo and HIPEC for ovarian cancer
This trial tests if adding a drug called a PARP inhibitor (which helps block cancer cells from repairing themselves) to standard chemotherapy and heated chemotherapy during surgery (HIPEC) can work better together for ovarian cancer that has already been treated with initial chemo. It is for people with a specific type of advanced ovarian cancer who are planning surgery after chemo.
AmsterdamAges 18–100 - NCT04282356RecruitingPhase 2
Test of strong chemotherapy delivered inside the abdomen
This Phase 2 trial tests an intensive treatment for advanced ovarian, fallopian tube, or primary peritoneal cancer. It combines planned surgery to remove visible tumor with chemotherapy that is put directly inside the abdomen during the operation, aiming to control the cancer more effectively.
MontpellierAges 18–75 - NCT06084195Recruiting
Study of ovarian cancer using advanced imaging
This trial uses a special imaging technique to study high-grade serous ovarian cancer. It aims to better understand the tumor to improve treatment. If you have advanced ovarian cancer and are scheduled for surgery, you may be eligible.
MontpellierAges 18 years+ - NCT07340164RecruitingPhase 2
Trastuzumab deruxtecan vs standard care for recurrent ovarian cancer
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
Seoul, SeoulAges 18 years+ - NCT07318558RecruitingPhase 3
Study of Sac-TMT for advanced ovarian cancer without HRD
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Birmingham, AlabamaAges 18 years+ - NCT06324175Recruiting
Spatial radiogenomics study for ovarian cancer
This study looks at how medical images relate to genetic patterns in high-grade serous ovarian cancer. It may help find better ways to diagnose and treat this specific type of ovarian cancer.
RomaAges 18 years+ - NCT06883487Recruiting
Exploring HER2 testing in high-grade ovarian cancer
This study looks at how to best detect the HER2 protein in high-grade serous ovarian cancer. The goal is to improve treatment choices for people with this type of cancer.
Guangzhou, GuangdongAges 18–75 - NCT07278336RecruitingPhase 1
Study of a new drug for advanced ovarian cancer
This trial tests a new drug called ABBV901, given alone or with other anticancer drugs, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and how it affects the body.
Duarte, CaliforniaAges 18 years+ - NCT06902467Recruiting
Chemotherapy directly into the abdomen after surgery for advanced ovarian cancer
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
MurciaAges 18–70 - NCT06907771Recruiting
Surgery strategy study for advanced ovarian cancer
This study looks back at records of people with advanced ovarian cancer to see if changing the order of their treatments might help them live longer. It focuses on those who had a certain type of surgery at a French hospital between 2010 and 2022.
StrasbourgAges 18 years+ - NCT07225270RecruitingPhase 3
Study of Rina-S plus care for ovarian cancer maintenance
This trial tests whether adding Rina-S to standard maintenance therapy helps prevent cancer from returning in people with recurrent platinum-sensitive ovarian cancer who have responded to second-line platinum-based chemotherapy.
Miami, FloridaAges 18 years+ - NCT06014528RecruitingPhase 2
IN10018 plus liposomal doxorubicin for platinum-resistant ovarian cancer
This trial tests if adding the drug IN10018 to standard chemotherapy (liposomal doxorubicin) can help women with ovarian cancer that has stopped responding to platinum-based treatments. It aims to see if the combination works better than chemotherapy alone.
BeijingAges 18 years+ - NCT07125391RecruitingPhase 2
Chemo plus propranolol before surgery for advanced ovarian cancer
This trial tests adding propranolol (a heart medication) to standard chemotherapy before surgery for advanced high-grade serous ovarian cancer. The goal is to see if this combination helps shrink tumors more effectively.
Hefei, AnhuiAges 18–75 - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT07100288Recruiting
Study of the ovary ligament in ovarian cancer patients
This trial looks at a specific ligament near the ovary in patients with epithelial ovarian cancer to better understand the disease. It is for people who had surgery with no cancer left behind.
Las Palmas de Gran CanariaAges 18 years+ - NCT07059845RecruitingPhase 2
Studying mirvetuximab combos for ovarian cancer
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
La Jolla, CaliforniaAges 18 years+ - NCT07030907RecruitingPhase 1
Testing OPB-101 for platinum-resistant ovarian cancer
This trial tests a new treatment called OPB-101 for people with a type of ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is to see if it is safe and if it can help shrink or slow the cancer.
Detroit, MichiganAges 18 years+ - NCT06976892RecruitingPhase 1
Idetrexed and Olaparib for ovarian cancer
This trial tests two drugs, idetrexed and olaparib, in people with a type of ovarian cancer that has stopped responding to standard treatments. It aims to see if this combination can help shrink or control the cancer.
Cambridge, CambridgeshireAges 18 years+ - NCT06954584RecruitingPhase 3
Fluzoparib with or without bevacizumab or diet for advanced ovarian cancer
This trial tests if adding bevacizumab (a drug that blocks blood vessel growth) or a special diet to fluzoparib (a PARP inhibitor) works better than fluzoparib alone for women with advanced ovarian cancer whose tumors have specific genetic features (HRD-positive or HRD-negative). It is for patients who have already responded well to initial chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06930755RecruitingPhase 1
Study of an oral drug for recurrent ovarian cancer
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
Peoria, IllinoisAges 18 years+
Hear when a new High Grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for high grade serous ovarian cancer?
- Yes. Clin2 currently lists 155 recruiting high grade serous ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a high grade serous ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a high grade serous ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.